Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07900867
PHASE2

This Study Will Evaluate the Effect and Safety of 626 in Patients With CLE

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

View on ClinicalTrials.gov

Summary

This study aims to evaluate the efficacy and safety of subcutaneous (SC) 626 versus placebo in adult participants with cutaneous lupus erythematosus (CLE).

Official title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SSGJ-626 in Participants With Active Cutaneous Lupus Erythematosus

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

140

Start Date

2026-11

Completion Date

2029-08

Last Updated

2026-10-28

Healthy Volunteers

No

Interventions

DRUG

Placebo

Placebo subcutaneous (SC) injection

Locations (2)

Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College.

Nanjing, Jiangsusheng, China

Peking University First Hospital

Beijing, China